WHAT DOES IMMUNOTHERAPY DO FOR LUNG CANCER PATIENT

lung cancer treatment

Immunotherapy is the process of either activating or suppressing the immune system to fight against the disease. The immune therapy that activates the immune response is known as activation immunotherapy and those therapies that decrease or suppress are called suppressive immunotherapy.

In years, immunotherapy is considered as a promising treatment of lung cancer.
It is a type of cancer treatment that activates the immunity to fight against cancer.
It's been decades, researchers have studied the role of the immune system in treating and preventing cancer.

Immunotherapy also can be addressed as biological therapy, is a type of cancer treatment designed to boost the body's natural defenses to fight cancer. The availability of several types of immunotherapy beyond checkpoint inhibitors, including cancer vaccines, monoclonal antibodies, and chimeric antigen receptor (CAR) T cells.

Immunotherapy became a key part of treating several different types of diseases.

But not all immunotherapies work the same way. Some immunotherapies boost your immune system overall, while others try to teach it in order to attack very specific types of cells found in tumors.

In 2015, Nivolumab was used for the treatment of non-small cell lung cancer (NSCLC).

In 2016, Atezolizumab was approved by FDA for treatment of metastatic non-small cell lung cancer (NSCLC).

In 2017, Pembrolizumab in combination with pemetrexed and carboplatin was used for non-small cell lung cancer (NSCLC) And In the year 2018, Atezolizumab was approved.

Targeted Therapy:

Patients who are carrying a lung tumor with EGFR or ALK gene mutations must be treated with targeted therapy rather than immunotherapy initially. For such patients, there is a higher chance that targeted therapy will shrink the tumor than that immunotherapy will work.

Erlotinib (Tarceva): Erlotinib 150 mg is used in the treatment of non-small cell lung cancer (NSCLC). Erlotinib is sold under the trade name Tarceva.

Erlotinib is differentiated as an epidermal growth factor receptor. It is a targeted drug therapy.
The epidermal growth factor receptor (EGFR) found on the surface of normal cells and many cancerous cells are blocked by erlotinib (Erlonat 150 mg).

Some limitations of using this drug are:
  • It is not recommended in use with combination with platinum-based chemotherapy
  • Safety and efficacy are avoided in NSCLC treatment.
Erlotinib tablets should be consumed orally either before or after eating. It is available in different concentrations of 25 mg, 100 mg, and 150 mg.

Some side effects of erlotinib tablets are: 

  • Diarrhea
  • Poor appetite
  • Fatigue
  • Cough
  • Nausea and vomiting
The erlotinib tablets must be consumed under doctor's consent.

Gefitinib: Gefitinib 250mg is a kinase inhibitor that is used in the treatment of metastatic non-small cell lung cancer (NSCLC).

The recommended use of Gefitinib is to uptake 250mg orally either one daily with or without food depending on the stage of the disease.

This 250 mg tablet is biconvex, brown, round having "IRESSA 250" marked on one side. One bottle contains 30 tablets of Gefitinib which should be stored at 20-25 degree Celsius.

Read: Does chemotherapy really cure lung cancer?

Comments

Post a Comment

Popular posts from this blog

Buy Trodelvy sacituzumab govitecan-hziy in India

  Trodelvy Overview: Trodelvy is widely prescribed by Oncologists for the treatment of patients with HR+/HER2- Metastatic Breast Cancer, Metastatic Triple-Negative Breast Cancer (mTNBC), and Metastatic Urothelial Cancer (mUC). It is considered a promising treatment option for those who are not ideal candidates for some conventional therapies. Developed by Immunomedics, Trodelvy 180 mg and Trodelvy 200 mg are two available commercial strengths. Worldwide, Trodelvy is promoted and facilitated by Gilead Sciences. Trodelvy is first approved on 22 April 2020. It is given by intravenous (IV) infusion by a health specialist. The medication received its (European Medicines Agency) EMA approval in October 2021. Trodelvy 180 mg and 200 mg injections are yet to be approved in India. The cost of Trodelvy in India usually depends on international factors. Buy Trodelvy from a Reliable Source: Many suppliers who are not authorized to handle or supply life-saving medicines such as Trodelvy found to b
Read more

Trodelvy: All about the drug

Image
Indication and Usage The medicine Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate drug, which is used in the treatment of adults suffering from locally advanced or metastatic triple-negative breast (mTNBC) cancer, HR+/HER2- metastatic breast cancer, and locally advanced or metastatic urothelial cancer (mUC). It is used when it is not possible to remove cancer with surgery. Trodelvy  comes in the form of single-dose vials in 180 mg for intravenous infusion. Dosage Its dosage is based on body weight, and the recommended dosage is 10 mg/kg administered intravenously once weekly on the first day and eighth day of a repeating 21-day cycle. Administration First infusion: The drug is infused in the body for 3 hours, and during the infusion, the patient is observed for any adverse reaction caused by the infusion. After 30 minutes of infusion, observation should be done again to check for any post-infusion reaction. Subsequent Infusion: If the drug is tolerated in t
Read more

What is Non-Small Cell Lung Cancer? What are the stages of NSCLC?

Image
NSCLC, the most common form of lung cancer. It occurs when the healthy cells in the lung change and start growing in an abnormal way, forming a specific mass addressed as tumor, lesion, or nodule. A tumor may develop anywhere in the lung and could be cancerous or benign. A cancerous tumor mainly is malignant, means, it has potential in order to spread to the rest part of the body. A benign tumor is the tumor that can grow but can not spread.  Non-Small Cell Lung Cancer (NSCLC) occurs in the epithelial cells. Doctors can also describe this form of Cancer (NSCLC) based on the type of the epithelial cell where the cancer usually starts.  Adenocarcinoma starts in cells that produce mucus.  Squamous carcinoma basically developed in the cells that line the airways.  Large cell carcinoma usually begins in the cells other than the two types which are described above.  It’s necessary for healthcare providers to distinguish between lung cancer that begins in the squamous cells from lung cancer
Read more